One Decision-Maker per Team: Inside Pfizer’s Cross-Functional Operating Model

Why It Matters

By collapsing layers of approval and centralising accountability, Pfizer boosts speed and agility, setting a benchmark for large organizations seeking to innovate faster in highly regulated markets.

Key Takeaways

• Single leader drives decisions, eliminating committee delays
• One governance layer acts like air traffic control
• Teams built with only essential functions, others as SMEs
• Workday ties performance reviews to pilot authority
• Scaling required new support for functional managers

Pulse Analysis

The urgency of the COVID‑19 vaccine race forced Pfizer to strip away traditional bureaucratic safeguards, proving that a lean decision‑making structure can deliver breakthrough results in months rather than years. This crisis‑driven agility sparked a broader rethink: if a single leader can steer a vaccine team through unprecedented timelines, the same principle could accelerate drug development pipelines, supply‑chain projects, and digital transformations across the company. By assigning clear ownership to a "pilot in command," Pfizer eliminates the inertia of multi‑layer committees, allowing rapid pivots and decisive action.

Central to the new model is the "air traffic control" governance layer, which monitors progress without micromanaging execution. Team composition is now purpose‑driven; core members are selected for direct impact, while subject‑matter experts are summoned on demand. Embedding this hierarchy into Workday’s performance system reinforces the shift, as project assessments flow from pilots rather than functional managers. This technical integration makes the authority map visible, reduces ambiguity, and aligns incentives with the organization’s speed‑first mindset.

For the broader industry, Pfizer’s rollout offers a template for balancing empowerment with oversight. The transition highlighted the need to re‑skill functional managers into coaching roles and to cultivate psychological safety so teams feel authorized to act without excessive approvals. As competitors watch Pfizer’s 700‑team network deliver consistent outcomes, the pilot‑centric approach may become a new standard for large, regulated enterprises aiming to replicate crisis‑level agility in everyday operations.